Clover Reports Positive Phase 2 Data for Respiratory Combination Vaccine Candidates
Clover Biopharmaceuticals has announced positive Phase 2 clinical trial results in older adults for its investigational combination vaccine candidates targeting RSV and hMPV, with potential inclusion of PIV3.
Clover Biopharmaceuticals announced positive Phase 2 clinical data from studies conducted in Australia for its combination vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), with potential inclusion of parainfluenza virus type 3 (PIV3).
The results support the company's view that these candidates may offer a differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines, aiming to restore and broaden protection.
The trial's objective was to assess the safety and immune response of the vaccines in older adults. Specific details on safety and efficacy are crucial for the company's next steps.
These positive findings are significant in the evolving RSV vaccine market. Clover's combination vaccine's potential advantages, such as the ability for re-vaccination, could position it competitively.